Omnix Medical
10 known investors
Omnix Medical is a biopharmaceutical company founded in 2015 that develops novel antibiotic agents to treat infections caused by drug-resistant bacteria. Its lead compound, OMN6, is a first-in-class antimicrobial in Phase II clinical trials targeting drug-resistant Acinetobacter baumannii infections.
BiotechHealthtech
Investors · 10
Entrée CapitalTel Aviv · $150K – $15M
Tal VenturesTel Aviv · $3M – $120M
OurCrowdreportedJerusalem · $604K – $65M
VLX VenturesreportedJerusalem · $700K – $1M
Also in the syndicate · 6
EIC FundleadEuropean Innovation Council (EIC) FundleadHarel Insurance & FinanceleadOriella LimitedPrevail PartnersXenia Ventures
Funding
SEC filings, press & company announcements$25M disclosed across 1 round · 2025
- $25MSeries COct 2025 · 3 sources
EIC Fund (lead), European Innovation Council (EIC) Fund (lead), Harel Insurance & Finance (lead), Entree Capital, Entrée Capital, Oriella Limited, OurCrowd, Prevail Partners, Tal Ventures, Xenia Ventures
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Omnix Medical do?
- Omnix Medical is a biopharmaceutical company founded in 2015 that develops novel antibiotic agents to treat infections caused by drug-resistant bacteria. Its lead compound, OMN6, is a first-in-class antimicrobial in Phase II clinical trials targeting drug-resistant Acinetobacter baumannii infections.
- Who are Omnix Medical's investors?
- Omnix Medical's investors include Entrée Capital, Tal Ventures, OurCrowd, VLX Ventures.
- How much funding has Omnix Medical raised?
- Omnix Medical has disclosed $25M raised across 1 round.